ArticleFrontiers in oncology2025
Case report and literature review: primary hepatic leiomyosarcoma with misdiagnosis and SDHB positive expression.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary hepatic leiomyosarcoma (PHL) is an extremely rare malignancy often misdiagnosed due to nonspecific imaging features overlapping with cholangiocarcinoma. This case highlights diagnostic challenges and the potential association of SDHB positivity with PHL prognosis. Case Presentation: A middle-aged male presented with an asymptomatic liver mass. Preoperative CT/MRI revealed a 10-cm lesion with progressive heterogeneous enhancement and delayed capsular enhancement, initially diagnosed as cholangiocarcinoma. Left hepatic lobectomy confirmed PHL. Immunohistochemistry showed SDHB positivity and low Ki67 (15%). The patient recovered well with no recurrence at 6-month follow-up. Conclusions: PHL can radiologically mimic cholangiocarcinoma, necessitating inclusion in differential diagnoses for "cholangiocarcinoma-like" liver masses. SDHB positivity may indicate favorable tumor biology, but further studies are needed to validate its prognostic value. Surgical resection remains curative for localized PHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.